Related Articles
Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells
Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α
Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: Gene amplification does not contribute to EGFR expression
Protein kinase C-α downregulates estrogen receptor-α by suppressing c-Jun phosphorylation in estrogen receptor-positive breast cancer cells
TP53 upregulates α‑smooth muscle actin expression in tamoxifen‑resistant breast cancer cells